Dr Reddys Laboratories (RDY) Change in Receivables (2009)
Dr Reddys Laboratories (RDY) posted quarterly Change in Receivables of $26.0 million for Q4 2009, up 271.43% on a QoQ basis from $7.0 million in Q3 2009.
Dr Reddys Laboratories (RDY) Change in Receivables (2009) Analysis & Trends
Dr Reddys Laboratories (RDY) has reported Change in Receivables for 1 consecutive years, with $26.0 million the latest figure, recorded in Q4 2009.
- Quarterly Change in Receivables changed N/A year-over-year to $26.0 million in Q4 2009, while the trailing twelve-month figure through Dec 2009 was -$23.8 million (changed N/A YoY) and the FY2026 annual result came in at -$72.0 million, up 40.0% from the prior year.
- Change in Receivables rose to $26.0 million in Q4 2009 per RDY's latest filing, from $7.0 million in the prior quarter.
- Over the last five years, Change in Receivables for RDY reached as high as $26.0 million in Q4 2009 and fell as low as $7.0 million in Q3 2009.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | -78.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 106.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -621.82 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | -38.20 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 126.30 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 81.40 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | - |
| 10 | Dr Reddys Laboratories | 9.82 Bn | 9.66 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2009 | 26.00 Mn |
| Dec 31, 2009 | 26.00 Mn |
| Sep 30, 2009 | 7.00 Mn |
| Sep 30, 2009 | 7.00 Mn |
| Jun 30, 2009 | 12.00 Mn |
| Jun 30, 2009 | 12.00 Mn |